A NEW SET OF PSYCHEDELIC MEDICINES
Dedicated to improving human health
through groundbreaking innovations
in psychedelic therapeutics.

Mission

WE ARE CREATING TRANSFORMATIVE MEDICINES TO
ADDRESS BIG PROBLEMS IN SOCIETY

The number of people with diabetes has increased by over 300 million since 1980. That number continues to rise. Diabetes is a major cause of kidney failure, blindness, stroke, heart attacks, and lower limb amputation. Conventional treatments are not working, we need an innovative approach.

The global prevalence of obesity has nearly tripled since 1975. Over 650 million adults worldwide are obese. Obesity is a major risk factor for diabetes, cardiovascular diseases, osteoarthritis, and some cancers. Mental health plays a key role as a cause and consequence of obesity and needs to be addressed in novel treatments for sustained results.

Stock Data

Here you will find the most recent Stock Data for Nova Mentis Life Science Corp. (CSE: NOVA)

 
Prev. Close  
MARKET CAP:
 
CHANGE:
 

Press Releases

BE FIRST TO KNOW WHAT IS HAPPENING IN OUR COMPANY

LATEST NEWS
See All
Nova Mentis Autism Clinical Study Approved by Institutional Review Board

Vancouver, British Columbia – February 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, …

READ MODE
Nova Mentis Expands Pre-Clinical Development Pipeline

Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug Vancouver, British Columbia – February 18 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) (“NOVA” or the “Company”), a leader …

READ MODE
Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board

Vancouver, British Columbia – February 11, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that …

READ MODE

Contact Us